Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Mauritius.
Press releases published on October 22, 2025
Onco3R Therapeutics reports first pre-clinical data from its best-in-class precision oncology portfolio at the 2025 AACR-NCI-EORTC symposium
Three posters to be presented featuring pre-clinical data of potential best-in-class FGFR3 selective inhibitor, SMARCA2 selective inhibitor, and P53 Y220C reactivator Candidates for FGFR3 and SMARCA2 programs identified: IND enabling studies anticipated in …
17a-4 offers eDisclaimer and WebParser Bundle for End-of-Year Savings
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- 17a-4’s eDisclaimer and WebParser are being offered as a bundle from now through year end. This limited-time offer is designed to help firms enhance compliance, manage web content efficiently, and maximize their …
Elevara Medicines Raises $70 Million Series A to Advance Phase 2 Rheumatoid Arthritis Trial and Expand Pipeline
Co-led by Forbion and Sofinnova Partners, along with founding investor Monograph Capital, and Weatherden Innovative lead program, ELV001, in-licensed by Elevara from Japan’s Teijin Pharma with good tolerability and safety, plus early signs of efficacy in …
Datavault AI Menunjuk Veteran Angkatan Laut AS Pete Scobell sebagai Wakil Presiden, Keamanan Global
BEAVERTON, Ore., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Datavault AI Inc. (Nasdaq: DVLT), yang menjadi pelopor dalam pengalaman data AI, valuasi, dan monetisasi, hari ini mengumumkan pengangkatan Pete Scobell sebagai Wakil Presiden, Keamanan Global. Sebagai …
データボルトAI (Datavault AI)、米海軍退役軍人ピート・スコベル (Pete Scobell) をグローバルセキュリティ担当副社長に任命
オレゴン州ビーバートン発, Oct. 22, 2025 (GLOBE NEWSWIRE) -- AIによるデータ体験、価値評価、収益化をリードするデータボルトAI (Datavault AI Inc.) (Nasdaq: DVLT) は本日、ピート・スコベルをグローバルセキュリティ担当副社長に任命したと発表した。米海軍特殊部隊 (U.S. Navy SEAL) の勲章受章退役軍人である同氏は、データボルトAIのグローバルセキュリティ業務、リスク管理、および全地域における実世界資産の物流活動の実行を統括する。 …
Datavault AI, 전 미 해군 네이비실 출신 피트 스코벨(Pete Scobell)을 글로벌 보안 부문 부사장으로 임명
오리건주 비버튼, Oct. 22, 2025 (GLOBE NEWSWIRE) -- AI 기반 데이터 경험, 가치 평가 및 수익화 분야를 선도하는 Datavault AI Inc. (나스닥: DVLT) 는 오늘 피트 스코벨(Pete Scobell) 을 글로벌 보안 부문 부사장 (Vice President, Global Security) 으로 임명했다고 발표했다. 미 해군 네이비 실(US Navy SEAL) 출신으로 다수의 훈장을 받은 스코벨은 앞으로 …
Datavault AI Melantik Veteran Tentera Laut AS Pete Scobell sebagai Naib Presiden Keselamatan Global
BEAVERTON, Oregon, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Datavault AI Inc. (Nasdaq: DVLT), peneraju dalam pengalaman, penilaian dan pengewangan data AI, hari ini mengumumkan pelantikan Pete Scobell sebagai Naib Presiden Keselamatan Global. Seorang veteran U.S. …
Datavault AI แต่งตั้งอดีตทหารผ่านศึกกองทัพเรือสหรัฐฯ Pete Scobell…
บีเวอร์ตัน รัฐออริกอน, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Datavault AI Inc. (Nasdaq: DVLT) ผู้นำด้านประสบการณ์ข้อมูล AI การประเมินมูลค่า และการสร้างรายได้ ประกาศแต่งตั้ง Pete Scobell เป็นรองประธานฝ่ายการรักษาความปลอดภัยระดับโลก Scobell อดีตหน่วย SEAL …
Datavault AI 任命美国海军退伍军人 Pete Scobell 为公司全球安全事务副总裁
比弗顿俄勒冈州, Oct. 22, 2025 (GLOBE NEWSWIRE) -- AI 数据体验、估值与变现领域的领先企业 Datavault AI Inc. (Nasdaq: DVLT) 今日宣布，任命 Pete Scobell 为公司全球安全事务副总裁。Scobell 退役自著名的美国海军海豹突击队，曾荣获授勋嘉奖，他将负责监督 Datavault AI 在全球范围内的安全运营、风险管理以及横跨所有地区的现实世界资产物流活动的执行。 Scobell 的任命正值 Datavault AI …
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
Year-to-date total sales growth of 12.1% at CER1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of full-year 2025 financial guidance based on slower than …
Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'année 2025 et revoit à la hausse ses prévisions pour l'exercice en cours
Croissance du chiffre d’affaires du Groupe de 12,1 % à taux de change constant1 au cours des neuf premiers mois de l’année 2025, ou 9,6 % en données publiées, portée par les trois aires thérapeutiques et incluant les solides performances d’Iqirvo®, Bylvay® …
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results …
Communiqué de presse : L’efdoralprine alfa de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase II sur l’emphysème par déficit en alpha-1-antitrypsine
L’efdoralprine alfa de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase II sur l’emphysème par déficit en alpha-1-antitrypsine L’efdoralprine alfa a démontré sa supériorité dans une une étude comparative …
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in first line unfit …
Ipsen annonce son intention d’acquérir ImCheck Therapeutics et étend son leadership en oncologie avec un portefeuille enrichi de produits en R&D
Acquisition axée sur le programme clinique phare ICT01 dans le domaine de la leucémie myéloïde aiguë, dont les données issues de l'essai EVICTION de phase I/II en cours ont montré une réponse thérapeutique élevée. ICT01 pourrait devenir une nouvelle norme …
ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Development of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
MELBOURNE, Australia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, announces today that it has …
Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, …
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients …
Safer Roads, Smarter Fleets: Geotab & Vitality Launch Data-Driven Behavioural Science Joint Venture
SYDNEY, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Geotab Inc. and its affiliates (“Geotab”), the global leader in connected vehicle and asset solutions, and Vitality, have formed a joint venture to improve driver safety and well-being, reduce risk and support …